



**GIG**  
CYMRU  
**NHS**  
WALES

Bwrdd Iechyd Prifysgol  
Cwm Taf Morgannwg  
University Health Board



## Freedom of Information Request: Our Reference CTMUHB\_343\_25

### You asked:

I am writing to request the following information under the FOIA.

**Q1. In the past 3 months [latest 3 months available] how many patients have received the following treatments [for any disease]:**

**Berinert (Human C1-esterase inhibitor)**

**Cinryze (Human C1-esterase inhibitor)**

**Orladeyo (Berotralstat)**

**Takhzyro (Lanadelumab)**

**Ruconest (Recombinant human C1-esterase inhibitor)**

**Firazyr (Icatibant injection)**

**Icatibant - any brand except Firazyr**

Please find below two tables populated with the data requested (Q1 & Q2). The period the data covers refers to 1<sup>st</sup> April 25 to 30<sup>th</sup> June 2025, the latest 3 months available.

| Medicine                                           | Number of Patients |
|----------------------------------------------------|--------------------|
| Berinert (Human C1-esterase inhibitor)             | 0                  |
| Cinryze (Human C1-esterase inhibitor)              | 0                  |
| Orladeyo (Berotralstat)                            | 0                  |
| Takhzyro (Lanadelumab)                             | 0                  |
| Ruconest (Recombinant human C1-esterase inhibitor) | 0                  |
| Firazyr (Icatibant injection)                      | 0                  |
| Icatibant - any brand except Firazyr               | 0                  |

**Q2. In the past 3 months how many patients have received the following treatment for any disease:**

**Octagam**

**Gamunex**

**Intratect**

**Kiovig**

**Gamten**

**Panzyga**

**Xembify**

**Cuvitru**

**Cutaquig**

**Hyqvia**

| <b>Medicine</b> | <b>Number of Patients</b> |
|-----------------|---------------------------|
| Octagam         | 0                         |
| Gamunex         | 16                        |
| Intratect       | **                        |
| Kiovig          | 0                         |
| Gamten          | 0                         |
| Panzyga         | 0                         |
| Xembify         | 0                         |
| Cuvitru         | 0                         |
| Cutaquig        | 0                         |
| Hyqvia          | 0                         |

Please note - Where the figures are less than 5, this has been denoted by \*\*. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

**Q3: In the past 3 months, how many patients have received any immunoglobulin treatment for the following diseases:**

**Primary immunodeficiency (PID)**

**Secondary immunodeficiency (SID)**

**Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)**

We can confirm that the Health Board does not centrally record this information.

Unfortunately, our electronic dispensing system does not record the condition for which the medicine is being prescribed.